| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02043756 | Neoplasms | Drug: Mitoxantrone Hydrochloride Liposome|Drug: Mitoxantrone | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | 2011-08-01 | 2014-01-21 |
| NCT00882076 | Leukemia | Drug: Etoposide, Mitoxantrone, Clofarabine|Drug: Clofarabine, Etoposide, Mitoxantrone | Milton S. Hershey Medical Center | Phase 1 | 2009-03-01 | 2014-12-04 |
| NCT01842672 | Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoblastic Lymphoma|Diffuse Large B-cell Lymphoma|Burkitt Lymphoma/Leukemia | Drug: Clofarabine|Drug: Mitoxantrone | New York Medical College | Phase 1|Phase 2 | 2013-03-01 | 2016-07-29 |
| NCT00660036 | Acute Myeloid Leukemia | Drug: Gemtuzumab ozogamicin|Drug: Mitoxantrone|Drug: Etoposide | University of Pittsburgh | Phase 1 | 2008-09-01 | 2016-01-14 |
| NCT00268242 | Leukemia | Drug: Gemcitabine Hydrochloride|Drug: Mitoxantrone Hydrochloride | The Cleveland Clinic|National Cancer Institute (NCI)|Duke University | Phase 2 | 2006-01-01 | 2015-08-30 |
| NCT00059631 | Prostate Cancer | Drug: Mitoxantrone (Novantrone)|Drug: Bortezomib (PS-341) | M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) | Phase 1 | 2003-03-01 | 2015-06-19 |
| NCT02131688 | Malignant Lymphoma | Drug: Mitoxantrone Hydrochloride Liposome | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | 2013-05-01 | 2014-05-04 |
| NCT01627938 | Multiple Sclerosis | Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Drug: Placebo plus Mitoxantrone (MX) | PD Dr. Andrew Chan|Ruhr University of Bochum | Phase 2 | 2012-04-01 | 2014-11-04 |
| NCT00940524 | Leukemia|Acute Lymphoblastic Leukemia | Drug: Dasatinib, Mitoxantrone, Cytarabine | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb | Phase 1 | 2009-07-01 | 2014-04-09 |
| NCT00447473 | Prostatic Neoplasms | Drug: GM-CSF|Drug: Ketoconazole|Drug: Mitoxantrone | The Methodist Hospital System|Bayer | Phase 2 | 2006-07-01 | 2016-03-15 |
| NCT01594918 | Metastatic Castration-resistant Prostate Cancer | Drug: Cabazitaxel|Drug: Mitoxantrone|Drug: Prednisone|Drug: Pegfilgrastim | Rahul Aggarwal|Sanofi|University of California, San Francisco | Phase 1 | 2012-06-01 | 2016-10-24 |
| NCT02021825 | Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorders | Drug: Mitoxantrone | Xuanwu Hospital, Beijing | Phase 4 | 2009-03-01 | 2013-12-19 |
| NCT00003858 | Prostate Cancer | Drug: mitoxantrone hydrochloride | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Phase 2 | | 2016-07-12 |
| NCT00203073 | Relapsing Remitting Multiple Sclerosis | Drug: glatiramer acetate 20 mg|Drug: glatiramer acetate 20 mg, with mitoxantrone | Teva Pharmaceutical Industries | Phase 2 | 2003-06-01 | 2011-04-13 |
| NCT00661492 | Androgen-independent Prostate Cancer | Drug: cetuximab|Drug: Mitoxantrone | US Oncology Research|ImClone LLC|Oregon Health and Science University | Phase 2 | 2008-05-01 | 2016-10-13 |
| NCT02596373 | Advanced Recurrent or Metastatic Breast Cancer | Drug: Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | 2015-06-01 | 2015-11-02 |
| NCT00901927 | Follicular Lymphoma | Drug: Bendamustine|Drug: Mitoxantrone|Drug: Rituximab | M.D. Anderson Cancer Center|Cephalon | Phase 2 | 2009-05-01 | 2016-05-26 |
| NCT01839240 | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | Drug: azacitidine|Drug: cytarabine|Drug: mitoxantrone hydrochloride|Other: laboratory biomarker analysis | University of Chicago|National Cancer Institute (NCI) | Phase 1 | 2012-06-01 | 2016-10-24 |
| NCT01214317 | Multiple Sclerosis | Procedure: plasmapheresis | Isfahan University of Medical Sciences | | 2010-01-01 | 2011-08-16 |
| NCT01260714 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | Drug: Azacitidine|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Mitoxantrone Hydrochloride | National Cancer Institute (NCI) | Phase 1 | 2010-12-01 | 2015-08-18 |
| NCT02686593 | Acute Myeloid Leukemia | Drug: Clofarabine, AraC, mitoxantrone (CLAM) | The University of Hong Kong | Phase 2 | 2016-02-01 | 2016-10-25 |
| NCT00304291 | Neuromyelitis Optica|Myelitis, Transverse|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System | Drug: Mitoxantrone | State University of New York at Buffalo|EMD Serono | Phase 4 | 2001-08-01 | 2006-11-27 |
